v3.26.1
Other Operating Income and Expenses - Schedule of Other Operating Income and Expenses (Details) - JPY (¥)
¥ in Millions
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
Other operating income:      
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 26) ¥ 0 ¥ 2,390 ¥ 0
Gain on sales of property, plant and equipment and investment property 165 363 144
Gain on divestment of business to Teva Takeda Yakuhin 18,265 10,198 7,832
Gain on divestment of business and subsidiaries (Note 18) 18,265 6,081 7,243
Other 6,318 13,262 11,404
Total 24,747 26,212 19,379
Other operating expenses:      
Donations and contributions 6,866 7,663 7,009
Restructuring expenses (Note 22) 70,818 128,133 81,358
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 26) 1,006 1,788 20,757
Valuation reserve for pre-launch inventories (reversal) 50,984 (7,313) 11,052
Impairment of assets held for sale (Note 18) 1,363 6,812 1,685
Provisions for legal proceedings related to AMITIZA (Note 31) 403,478 0 0
Other 24,466 69,650 84,666
Total 558,979 206,733 206,527
Teva Takeda Pharma Ltd.      
Other operating income:      
Gain on divestment of business to Teva Takeda Yakuhin ¥ 0 ¥ 4,117 ¥ 588